SCHEMBL4489374

SCHEMBL4489374

COC(=O)c1c(F)ccc2c1OCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 1/20 0.43
ATM Q13315 1/20 0.43
NPC1 O15118 8/20 0.43
RAB9A P51151 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
TP53 P04637 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CASP3 P42574 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
HTT P42858 2/20 0.41
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TARBP2 Q15633 1/20 0.39
LMNA P02545 2/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30843235 1.00 KDM4E (0.43) KDM4EALDH1A1HPGDATMNPC1
SCHEMBL30843197 0.88 SMN1; SMN2 (0.43) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL7851584 0.81 KDM4E (0.42) KDM4EALDH1A1HPGDATMNPC1
SCHEMBL8470586 0.81 AOC3 (0.44) KDM4EALDH1A1HPGDATMNPC1
SCHEMBL31353412 0.81 KDM4E (0.42) KDM4EALDH1A1HPGDATMNPC1
SCHEMBL4493633 0.80 ALDH1A1 (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL10621687 0.80 HPGD (0.43) KDM4EALDH1A1HPGDATMNPC1
SCHEMBL30843242 0.78 RAB9A (0.46) KDM4EHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL31216676 0.76 KDM4E (0.45) KDM4EALDH1A1HPGDATMNPC1
SCHEMBL23856764 0.75 CA1 (0.54) KDM4EALDH1A1ATMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501516-B2 Quinoline derivatives and their use as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2009-03-10 US disclosed
EP-1409481-B1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-10-04 EP disclosed
US-20050009867-A1 Quinoline derivatives and their use as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2005-01-13 US disclosed
WO-2003047582-A1 QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS ASTRAZENECA AB (SE) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009867-A1 Quinoline derivatives and their use as tyrosine kinase inhibitors ABL1, FLT3, JAK2 KDM4E 1156/4885ALDH1A1 3215/4885HPGD 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.